Illuccix China Phase 3 Study Completes Enrolment
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient...